Similar articles

• Ceftobiprole for Staphylococcus aureus Bacteremia.

  Huang PY, Lai CC. Huang PY, et al. N Engl J Med. 2023 Dec 28;389(26):2498. doi: 10.1056/NEJMc2312883. N Engl J Med. 2023. PMID: 38157514 No abstract available.
• Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.

  Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr; ERADICATE Study Group. Holland TL, et al. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/NEJMoa2300220. Epub 2023 Sep 27. N Engl J Med. 2023. PMID: 37754204 Clinical Trial.
• Ceftobripole: Experience in staphylococcal bacteremia.

  Soriano A, Morata L. Soriano A, et al. Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):24-28. Rev Esp Quimioter. 2019. PMID: 31364338 Free PMC article. Review.
• Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.

  Hamed K, Engelhardt M, Jones ME, Saulay M, Holland TL, Seifert H, Fowler VG Jr. Hamed K, et al. Future Microbiol. 2020 Jan;15(1):35-48. doi: 10.2217/fmb-2019-0332. Epub 2020 Jan 10. Future Microbiol. 2020. PMID: 31918579 Free PMC article.
• Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.

  Gudiol C, Cuervo G, Shaw E, Pujol M, Carratalà J. Gudiol C, et al. Expert Opin Pharmacother. 2017 Dec;18(18):1947-1963. doi: 10.1080/14656566.2017.1403585. Epub 2017 Dec 4. Expert Opin Pharmacother. 2017. PMID: 29115883 Review.